Paula Simplicio da Silva

Prof. Dr. Paula Simplicio da Silva

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2018 in Journal of the International AIDS Society
Verified
Journal Article
Open access
PDF file
HPHugo Perazzo
Hugo Perazzo
SCSandra W. Cardoso
Sandra W. Cardoso
CYCarolyn Yanavich
Carolyn Yanavich
ENEstevão P Nunes
Estevão P Nunes
MMMichelle Morata
Michelle Morata
BGBeatriz Grinsztejn
Beatriz Grinsztejn
Introduction: Non‐alcoholic fatty liver disease is characterized by the presence of hepatic steatosis and can be associated with fibrosis progression, development of cirrhosis and liver‐related complications. Data on the prevalence of liver fibrosis and steatosis in HIV patients remain contradictory in resource‐limited settings. We aimed to describe the prevalence and factors associated with liver fibrosis and steatosis in patients with HIV mono‐infection under long‐term antiretroviral therapy ( ART ) in Rio de Janeiro, Brazil. Methods: Clinical assessment, fasting blood collection and liver stiffness measurement ( LSM )/controlled attenuation parameter ( CAP ) by transient elastography were performed on the same day for this cross‐sectional study ( PROSPEC ‐ HIV study; NCT 02542020). Patients with viral hepatitis co‐infection, ART ‐naïve or missing data were excluded. Liver fibrosis and steatosis were defined by LSM ≥ 8.0 kPa and CAP ≥ 248 dB/m respectively. HIV history, cumulative and current ART regimens were evaluated. Multivariate logistic regression models adjusted for age and gender were performed. Results: In total, 395 patients (60% female; median age of 45 (IQR, 35 to 52) years, body mass index = 25.7 (23.2 to 29.4) kg/m 2 , alanine aminotransferase = 30 (23 to 42) IU/L, duration of ART for 7 (4 to 14) years) were included. LSM and CAP were reliable in 93% (n = 367) and 87% (n = 344) respectively. The prevalence of fibrosis and steatosis were 9% (95% confidence interval (CI), 7 to 13) and 35% (95% CI, 30 to 40) respectively. The following factors were associated with fibrosis (odds ratio (OR) (95% CI)): older age (per 10 years; 1.80 (1.27 to 2.55); p = 0.001) and CD4+ count <200 cells/mm 3 (7.80 (2.09 to 29.09), p = 0.002). Type 2 diabetes had a trend towards the presence of liver fibrosis (2.67 (0.96 to 7.46), p = 0.061). Central obesity (10.74 (4.40 to 26.20), p < 0.001), type 2 diabetes (9.74 (3.15 to 30.10), p < 0.001), dyslipidaemia (2.61 (1.35 to 5.05), p = 0.003) and metabolic syndrome (4.28 (2.45 to 7.46), p < 0.001) were associated with steatosis. A dominant backbone ART regimen of zidovudine ( AZT ), d4T, ddI or ddC was associated with steatosis (1.90 (1.07 to 3.38), p = 0.028) independently of metabolic features. Conclusion: Integrated strategies for preventing non‐communicable diseases in people with HIV mono‐infection are necessary to decrease the burden of liver diseases. Clinical Trial Number: NCT02542020.

1 June 2016 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
MMMauro Felippe Felix Mediano
Mauro Felippe Felix Mediano
FMFernanda de Souza Nogueira Sardinha Mendes
Fernanda de Souza Nogueira Sardinha Mendes
VPVivian Liane Mattos Pinto
Vivian Liane Mattos Pinto
GSGilberto Marcelo Sperandio da Silva
Gilberto Marcelo Sperandio da Silva
PSPaula Simplicio da Silva
Paula Simplicio da Silva
ASAndrea Silvestre de Sousa
Andrea Silvestre de Sousa
The benefit of a cardiac rehabilitation (CR) program for patients with Chagas heart failure (CHF) remains unclear. Therefore, we aimed to investigate the effects of CR for CHF patients. A single-arm pilot study, including 12 patients with CHF, was performed. Patients participated in an 8-month physical exercise intervention, comprising aerobic, strength, and stretching exercises (3 times per week, 60 minutes per session). Nutritional and pharmaceutical counseling were also performed. Functional capacity (cardiopulmonary exercise test), muscle respiratory strength (manovacuometry), and body composition (anthropometry and skinfolds) were evaluated at baseline, and after 4 and 8 months of intervention. Cardiac function (echocardiography), biomarkers (lipid profile, glucose, and glycated hemoglobin) and quality of life (Minnesota Living with Heart Failure Questionnaire) were assessed at baseline and at the end of the intervention. Seven of 12 patients included in the study completed the 8-month follow-up period. Only 2 moderate adverse events occurred during the exercise training. Functional capacity improved after 4 months of CR, while left ventricular ejection fraction (LVEF) and respiratory strength improved after 8 months. Patients with right ventricular (RV) dysfunction at baseline exhibited an improvement in functional capacity after 4 months, and improvements in left ventricular (LV) diastolic pressure, respiratory strength, and quality of life at the end of follow-up. Conversely, those with normal baseline RV function demonstrated LVEF increases that were not observed in patients with RV dysfunction. CR was feasible, safe, and has important clinical benefits for patients with CHF, specifically for cardiac function and muscle respiratory strength.

1 May 2020 in The American Journal of Cardiology
Verified
Journal Article
Closed access
FMFernanda de Souza Nogueira Sardinha Mendes
Fernanda de Souza Nogueira Sardinha Mendes
MMMauro Felippe Felix Mediano
Mauro Felippe Felix Mediano
FSFernando Cesar de Castro e Souza
Fernando Cesar de Castro e Souza
PSPaula Simplicio da Silva
Paula Simplicio da Silva
FCFernanda Martins Carneiro
Fernanda Martins Carneiro
ASAndréa Silvestre de Sousa
Andréa Silvestre de Sousa

2 April 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IXIsis Gabrielli Gomes Xavier
Isis Gabrielli Gomes Xavier
MVMarcelo Carvalho Vieira
Marcelo Carvalho Vieira
LJLuiz Fernando Rodrigues Junior
Luiz Fernando Rodrigues Junior
GSGilberto Marcelo Sperandio da Silva
Gilberto Marcelo Sperandio da Silva
PSPaula Simplicio da Silva
Paula Simplicio da Silva
MMMauro Felippe Felix Mediano
Mauro Felippe Felix Mediano
The increase in life expectancy and the migration of individuals with Chagas disease (ChD) from rural to urban centers exposes them to the development of chronic-degenerative abnormalities that may increase the prevalence of metabolic syndrome (MetS). The present study aimed to identify the prevalence of MetS and its components in individuals with chronic ChD. This is a cross-sectional study with 361 patients of both sexes, aging >18 years, followed at a national reference center (Rio de Janeiro, Brazil). MetS diagnosis followed the International Diabetes Federation 2005 criteria. The association between the variables was determined through logistic regression models. The mean age was and 60.7±10.8 years. About half (56.2%) were female and the majority self-reported their race as mulatto (59.8%). The percentage of individuals with MetS was 40.4%. The variables independently associated with MetS were age (OR 1.06; 95%CI 1.04–1.09), high education levels (OR 0.36; 95%CI 0.17–0.79) and cardiac form with heart failure (OR 0.34; 95%CI 0.17–0.68). Therefore, a high prevalence of MetS was found in this Brazilian chronic ChD cohort. The identification of the associated factors can facilitate the development of effective approaches for preventing and managing MetS in ChD patients.

1 June 2017 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
PDF file
MMMauro Felippe Felix Mediano
Mauro Felippe Felix Mediano
FMFernanda de Souza Nogueira Sardinha Mendes
Fernanda de Souza Nogueira Sardinha Mendes
VPVivian Liane Mattos Pinto
Vivian Liane Mattos Pinto
PSPaula Simplicio da Silva
Paula Simplicio da Silva
AHAlejandro Marcel Hasslocher-Moreno
Alejandro Marcel Hasslocher-Moreno
ASAndrea Silvestre de Sousa
Andrea Silvestre de Sousa
Keywords: Chagas heart failure; Cardiac rehabilitation; Quality of life

2 September 2016 in Trials
Verified
Journal Article
Open access
PDF file
FMFernanda de Souza Nogueira Sardinha Mendes
Fernanda de Souza Nogueira Sardinha Mendes
Andrea Silvestre de SousaAndrea Silvestre de Sousa
Andrea Silvestre de Sousa
FSFernando Cesar de Castro Cesar Souza
Fernando Cesar de Castro Cesar Souza
VPVivian Liane Mattos Pinto
Vivian Liane Mattos Pinto
PSPaula Simplicio da Silva
Paula Simplicio da Silva
MMMauro Felippe Felix Mediano
Mauro Felippe Felix Mediano
The effects of exercise training on Chagas heart disease are still unclear. This study aimed to evaluate the effect of exercise training over functional capacity, cardiac function, quality of life, and biomarkers in Chagas heart disease. The PEACH study is a superiority randomized clinical trial which will include subjects who meet the following criteria: Chagas heart disease with a left ventricular ejection fraction below 45 % with or without heart failure symptoms; clinical stability in the last 3 months; adherence to clinical treatment; and age above 18 years. The exclusion criteria are: pregnancy; neuromuscular limitations; smoking; evidence of non-chagasic heart disease; systemic conditions that limit exercise practice or cardiopulmonary exercise test; unavailability to attend the center three times a week during the intervention period; and practitioners of regular exercise. The intervention group will perform an exercise training intervention three times per week during 6 months and will be compared to the control group without exercise. Both groups will undergo the same monthly pharmaceutical and nutritional counseling as well as standard medical treatment according to the Brazilian consensus on Chagas disease. The primary outcome is functional capacity based on peak exercise oxygen consumption during cardiopulmonary exercise testing. Secondary outcomes are: cardiac function; body composition; muscle respiratory strength; microvascular reactivity; cardiac rhythm abnormalities; autonomic function; biochemical; oxidative stress and inflammatory biomarkers; and quality of life. Subjects will be evaluated at baseline, and at 3 and 6 months after randomization. Thirty patients will be randomly assigned into exercise or control groups at a ratio of 1:1. Findings of the present study will be useful to determine if physical exercise programs should be included as an important additional therapy in the treatment of patients with Chagas heart disease. ClinicalTrials.gov ID: NCT02517632 (registered on 6 August 2015).